newsfilter
← Latest News
GlobeNewswire·

NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

A JDRF funded grant will be used to explore the combination of NexImmune's antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc.�